Analysts' Top 5 Price Targets of July 23, 2025
Reading Time: 4 minutes
BioMarin Pharmaceuticals [US09061G1013] Leerink Partners reaffirms Buy rating with a price target of $105 (77% upside potential) The focus is on the expansion of the use of Voxzogo , a medication for the treatment of achondroplasia, which is now also to be used for other dwarfism disorders. This indication expansion could give BioMarin access to new patient groups and significantly increase revenue potential. Another promising growth driver is BMN351, a drug candidate for the treatment of Duchenne muscular dystrophy. BioMarin is...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
